{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T21:15:35Z","timestamp":1774905335622,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":294,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,3]]},"DOI":"10.1046\/j.1365-2230.2001.00779.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T10:02:05Z","timestamp":1047376925000},"page":"127-131","source":"Crossref","is-referenced-by-count":68,"title":["A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders"],"prefix":"10.1093","volume":"26","author":[{"given":"S.","family":"Jolles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins: a system for the separation into fractions of the protein and lipoprotein components of biological fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J Am Chem Soc"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/bmj.316.7135.936","article-title":"Management of aseptic meningitis secondary to intravenous immunoglobulin","volume":"316","author":"Jolles","year":"1998","journal-title":"BMJ"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archderm.134.1.80","article-title":"Dermatological uses of high-dose intravenous immunoglobulin","volume":"134","author":"Jolles","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2165\/00002018-199309040-00003","article-title":"Adverse effects of intravenous immunoglobulin","volume":"9","author":"Misbah","year":"1993","journal-title":"Drug Safety"},{"issue":"Suppl. 1","key":"10.1046\/j.1365-2230.2001.00779.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cei.1996.104.s1.3","article-title":"Mechanisms of action of intravenous immune globulin in immune-mediated diseases","volume":"104","author":"Mouthon","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/0140-6736(93)91784-J","article-title":"Immunologically active proteins in intravenous immunoglobulin","volume":"342","author":"Lam","year":"1993","journal-title":"Lancet"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB8|cit8","first-page":"1316","volume-title":"Clinical Immunology Principles and Practice.","author":"Hall","year":"1996"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(89)80148-3","article-title":"High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid","volume":"20","author":"Tappeiner","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0190-9622(08)80783-9","article-title":"Effects of intravenous gamma-globulin in pemphigus","volume":"22","author":"Humbert","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2133.1995.tb02631.x","article-title":"Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients","volume":"133","author":"Beckers","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2133.1996.d01-949.x","article-title":"Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy","volume":"135","author":"Bewley","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1365-2133.1995.tb06952.x","article-title":"High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris","volume":"133","author":"Messer","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0190-9622(99)70516-5","article-title":"Therapeutic failure of high-dose intravenous immunoglobulin in pemphigus vulgaris","volume":"40","author":"Jolles","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB15|cit15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1046\/j.1365-2133.1999.02817.x","article-title":"High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases","volume":"140","author":"Harman","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1046\/j.1365-2133.1998.02297.x","article-title":"Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy?","volume":"138","author":"Colonna","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-2133.1996.tb03913.x","article-title":"Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy","volume":"135","author":"Wever","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"964","DOI":"10.7326\/0003-4819-103-6-965_1","article-title":"Bullous pemphigoid and intravenous gammaglobulin","volume":"103","author":"Godard","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/S0161-6420(99)90496-7","article-title":"Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study","volume":"106","author":"Foster","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2133.1997.tb03770.x","article-title":"Cicatricial pemphigoid treated with intravenous immunoglobulin","volume":"137","author":"Urcelay","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0190-9622(09)80064-9","article-title":"Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins","volume":"31","author":"Caldwell","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0190-9622(97)80411-2","article-title":"Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita","volume":"36","author":"Kofler","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0190-9622(93)70189-Z","article-title":"Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins","volume":"29","author":"Meier","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1365-2133.1995.tb00735.x","article-title":"Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins","volume":"132","author":"Mohr","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0190-9622(99)70504-9","article-title":"Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy","volume":"40","author":"Khan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB26|cit26","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1046\/j.1365-2133.2000.03395.x","article-title":"High-dose intravenous immune globulin is also effective in linear IgA disease","volume":"142","author":"Kroiss","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2230.1998.00342.x","article-title":"A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin","volume":"23","author":"Hern","year":"1998","journal-title":"Clin Exp Dermatol"},{"key":"10.1046\/j.1365-2230.2001.00779.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1046\/j.1365-2133.1998.2576m.x","article-title":"Severe,\u00a0refractory epidermolysis bullosa acquisita complicated by an oesophageal stricture responding to intravenous immune globulin","volume":"139","author":"Harman","year":"1998","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2230.2001.00779.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2230.2001.00779.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1046\/j.1365-2230.2001.00779.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T12:00:24Z","timestamp":1676376024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/26\/2\/127\/6631143"}},"subtitle":["hdIVIg treatment of autoimmune blistering disorders"],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,3]]}},"URL":"https:\/\/doi.org\/10.1046\/j.1365-2230.2001.00779.x","archive":["Portico"],"relation":{},"ISSN":["0307-6938"],"issn-type":[{"value":"0307-6938","type":"print"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}